racotumomab

Home
Ligands
racotumomab

GtoPdb Ligand ID: 7995

Synonyms: 1E10 | Vaxira®

racotumomab is an approved drug (Cuba and Argentina (2013))

Comment: Racotumomab is an anti-idiotype therapeutic cancer vaccine directed against the ganglioside N-glycolil (NGc) GM3 [2,5], which has been identified on the cell surface of malignant cells from lung [4] and breast tumours [8], melanoma [10-11], and neuroectodermal pediatric tumours [6-7,12-13]. Racotumomab is being investigated for its antineoplastic activity.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

References
1. Alfonso M, Díaz A, Hernández AM, Pérez A, Rodríguez E, Bitton R, Pérez R, Vázquez AM. (2002) An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol, 168 (5): 2523-9. [PMID:11859147]
2. Gajdosik Z. (2014) Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer. Drugs Today, 50 (4): 301-7. [PMID:24918647]
3. Grant SC, Kris MG, Houghton AN, Chapman PB. (1999) Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin. Clin Cancer Res, 5 (6): 1319-23. [PMID:10389914]
4. Hayashi N, Chiba H, Kuronuma K, Go S, Hasegawa Y, Takahashi M, Gasa S, Watanabe A, Hasegawa T, Kuroki Y et al.. (2013) Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody. Cancer Sci, 104 (1): 43-7. [PMID:23004020]
5. Hernández AM, Vázquez AM. (2015) Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer. Expert Rev Vaccines, 14 (1): 9-20. [PMID:25420897]
6. Inoue S, Sato C, Kitajima K. (2010) Extensive enrichment of N-glycolylneuraminic acid in extracellular sialoglycoproteins abundantly synthesized and secreted by human cancer cells. Glycobiology, 20 (6): 752-62. [PMID:20197272]
7. Malykh YN, Schauer R, Shaw L. (2001) N-Glycolylneuraminic acid in human tumours. Biochimie, 83 (7): 623-34. [PMID:11522391]
8. Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, Perez R, Ando S. (1996) Gangliosides expressed in human breast cancer. Cancer Res, 56 (22): 5165-71. [PMID:8912852]
9. McCaffery M, Yao TJ, Williams L, Livingston PO, Houghton AN, Chapman PB. (1996) Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin Cancer Res, 2 (4): 679-86. [PMID:9816218]
10. Nakarai H, Chandler PJ, Kano K, Morton DL, Irie RF. (1990) Hanganutziu-Deicher antigen as a possible target for immunotherapy of melanoma. Int Arch Allergy Appl Immunol, 91 (3): 323-8. [PMID:2354874]
11. Nakarai H, Saida T, Shibata Y, Irie RF, Kano K. (1987) Expression of heterophile, Paul-Bunnell and Hanganutziu-Deicher antigens on human melanoma cell lines. Int Arch Allergy Appl Immunol, 83 (2): 160-6. [PMID:3294601]
12. Scursoni AM, Galluzzo L, Camarero S, Lopez J, Lubieniecki F, Sampor C, Segatori VI, Gabri MR, Alonso DF, Chantada G et al.. (2011) Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer. Clin Dev Immunol, 2011: 245181. [PMID:21941577]
13. van Cruijsen H, Ruiz MG, van der Valk P, de Gruijl TD, Giaccone G. (2009) Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer, 9: 180. [PMID:19519895]
14. Yao TJ, Meyers M, Livingston PO, Houghton AN, Chapman PB. (1999) Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res, 5 (1): 77-81. [PMID:9918205]

References

1. Alfonso M, Díaz A, Hernández AM, Pérez A, Rodríguez E, Bitton R, Pérez R, Vázquez AM. (2002)
An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients.
J Immunol, 168 (5): 2523-9. [PMID:11859147]

2. Gajdosik Z. (2014)
Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer.
Drugs Today, 50 (4): 301-7. [PMID:24918647]

3. Grant SC, Kris MG, Houghton AN, Chapman PB. (1999)
Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin.
Clin Cancer Res, 5 (6): 1319-23. [PMID:10389914]

4. Hayashi N, Chiba H, Kuronuma K, Go S, Hasegawa Y, Takahashi M, Gasa S, Watanabe A, Hasegawa T, Kuroki Y et al.. (2013)
Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody.
Cancer Sci, 104 (1): 43-7. [PMID:23004020]

5. Hernández AM, Vázquez AM. (2015)
Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer.
Expert Rev Vaccines, 14 (1): 9-20. [PMID:25420897]

6. Inoue S, Sato C, Kitajima K. (2010)
Extensive enrichment of N-glycolylneuraminic acid in extracellular sialoglycoproteins abundantly synthesized and secreted by human cancer cells.
Glycobiology, 20 (6): 752-62. [PMID:20197272]

7. Malykh YN, Schauer R, Shaw L. (2001)
N-Glycolylneuraminic acid in human tumours.
Biochimie, 83 (7): 623-34. [PMID:11522391]

8. Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, Perez R, Ando S. (1996)
Gangliosides expressed in human breast cancer.
Cancer Res, 56 (22): 5165-71. [PMID:8912852]

9. McCaffery M, Yao TJ, Williams L, Livingston PO, Houghton AN, Chapman PB. (1996)
Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.
Clin Cancer Res, 2 (4): 679-86. [PMID:9816218]

10. Nakarai H, Chandler PJ, Kano K, Morton DL, Irie RF. (1990)
Hanganutziu-Deicher antigen as a possible target for immunotherapy of melanoma.
Int Arch Allergy Appl Immunol, 91 (3): 323-8. [PMID:2354874]

11. Nakarai H, Saida T, Shibata Y, Irie RF, Kano K. (1987)
Expression of heterophile, Paul-Bunnell and Hanganutziu-Deicher antigens on human melanoma cell lines.
Int Arch Allergy Appl Immunol, 83 (2): 160-6. [PMID:3294601]

12. Scursoni AM, Galluzzo L, Camarero S, Lopez J, Lubieniecki F, Sampor C, Segatori VI, Gabri MR, Alonso DF, Chantada G et al.. (2011)
Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer.
Clin Dev Immunol, 2011: 245181. [PMID:21941577]

13. van Cruijsen H, Ruiz MG, van der Valk P, de Gruijl TD, Giaccone G. (2009)
Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer.
BMC Cancer, 9: 180. [PMID:19519895]

14. Yao TJ, Meyers M, Livingston PO, Houghton AN, Chapman PB. (1999)
Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies.
Clin Cancer Res, 5 (1): 77-81. [PMID:9918205]